Cancer Targeted Therapy

CRBN ligand-822 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-822 can be linked to a target protein ligand via a linker to form a PROTAC.

GSK2256098 (Standard) is the analytical standard of GSK2256098 (HY-100498). This product is intended for research and analytical applications. GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

Tasquinimod (Standard) is the analytical standard of Tasquinimod. This product is intended for research and analytical applications. Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor.

CRBN ligand-461 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-461 can be linked to a target protein ligand via a linker to form a PROTAC.

Amino-PEG12-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

EC330 (Standard) is the analytical standard of EC330 (HY-100949). This product is intended for research and analytical applications. EC330 is a leukemia inhibitory factor (LIF) inhibitor. EC330 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).

Monomethyl auristatin E intermediate-13 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs).

Benzyl (4-aminobutyl)carbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

CRBN ligand-710 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-710 can be linked to a target protein ligand via a linker to form a PROTAC.

mTOR inhibitor-24 (comounp 9d) is a mTOR inhibitor, with IC₅₀s of 0.34 nM (mTOR) and 324 nM (PI3K-α) respectively. mTOR inhibitor-24 inhibtis LNCaP cell proliferation (IC₅₀: 180 nM).

(S)-TCO-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

CRBN ligand-840 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-840 can be linked to a target protein ligand via a linker to form a PROTAC.

Thalidomide-O-amido-C3-COOH (Standard) is the analytical standard of Thalidomide-O-amido-C3-COOH (HY-103612). This product is intended for research and analytical applications. Thalidomide-O-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HPK1-IN-53 (compund 3a) is the potent HPK1 inhibitor (IC₅₀=48 nM).

2-Deacetyl-4-tigloylchamissionolide is a heliangolide-type sesquiterpene lactone, a derivative of Chamissonolide (HY-N19727), and a cytotoxic agent. 2-Deacetyl-4-tigloylchamissionolide exerts cytotoxicity via alkylating biological nucleophiles, targeting free thiol groups in proteins to interfere with their functions. 2-Deacetyl-4-tigloylchamissionolide exhibits different chromatographic behaviors in TLC and HPLC. 2-Deacetyl-4-tigloylchamissionolide can be used for the research of Ehrlich ascites carcinoma.

HLI98C is a ubiquitin ligase inhibitor. HLI98C inhibits p53 ubiquitylation. HLI98C inhibits HDM2 auto-ubiquitylation.

Fmoc-NH-CH2-PEG3-C2-NH2 (hydrochloride) is a PROTAC linker that can be used in the synthesis of PROTACs.

MG-002 is an orally active eIF4A1 and eIF4A2 inhibitor with a human eIF4A1 IC₅₀ of 43 nM. MG-002 prevents competent ribosome recruitment to mRNA, inhibits cap-dependent mRNA translation, and engages eIF4A2 via the same RNA clamping mechanism to inhibit mRNA translation. MG-002 induces G2/M cell cycle delay, induces apoptosis, suppresses synthesis of c-MYC and cyclin D1, and shows minimal overt toxicity in mice. MG-002 inhibits primary triple-negative breast cancer tumor growth, attenuates metastatic spread, and enhances anti-neoplastic activity of Doxorubicin (HY-15142A) in pre-clinical models.

Ethyl 2-(3-chloropropoxy)acetate is a PROTAC linker that can be used in the synthesis of PROTACs.